Skip to main content
. 2016 Dec 27;61(1):e00899-16. doi: 10.1128/AAC.00899-16

FIG 2.

FIG 2

Model-based simulations of rilpivirine at 25 mg QD (A), 50 mg QD (B), and 25 mg BID (C) in HIV-positive individuals. Solid lines, population median prediction (PI50%) from the model; shaded areas, 95% prediction intervals; dashed line, proposed target value of 50 ng/ml; dotted line, high concentration that could lead to a significant QTc prolongation.